Juan A. Merino-Garcia

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.

Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: June 24, 2024

Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.

Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.

Journal: Multiple sclerosis and related disorders

Published: September 19, 2023

The Multiple Sclerosis Data Alliance Catalogue: Enabling Web-Based Discovery of Metadata from Real-World Multiple Sclerosis Data Sources.

The Multiple Sclerosis Data Alliance Catalogue: Enabling Web-Based Discovery of Metadata from Real-World Multiple Sclerosis Data Sources.

Journal: International journal of MS care

Published: January 17, 2022

Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies.

Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies.

Journal: Neurodegenerative disease management

Published: May 10, 2021

CSF Chitinase 3-Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis.

CSF Chitinase 3-Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: February 26, 2021

Descriptive analysis of the electroencephalogram in Angelman syndrome

Descriptive analysis of the electroencephalogram in Angelman syndrome

Journal: Revista de neurologia

Published: January 13, 2021

Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study.

Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study.

Journal: CNS drugs

Published: November 05, 2020

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.

Journal: Frontiers in neurology

Published: July 02, 2020

12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (II).

12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (II).

Journal: Revista de neurologia

Published: May 22, 2020

12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (I)

12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (I)

Journal: Revista de neurologia

Published: May 12, 2020

Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population.

Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population.

Journal: Journal of neurology

Published: February 11, 2020

Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement.

Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement.

Journal: Neurologia

Published: January 20, 2020

Showing 1-12 of 40

Last Updated: 09/26/2026